参考文献
［1] WATTS G F，GIDDING S S，MATA P，et al. Familial hypercholesterolaemia：evolving knowledge for designing adaptive models of care［J］. Nat Rev Cardiol，2020，17（6）：360-377.
［2] FELLMANN F，VAN EL C G，CHARRON P，et al. European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death［J］. Eur J Hum Genet，2019，27（12）：1763-1773.
［3] MANGSET M，HOFMANN B. LQTS parents' reflections about genetic risk knowledge and their need to know or not to know their children's carrier status［J］. J Genet Couns，2014，23（6）：1022-1033.
［4] ERBEL R，ABOYANS V，BOILEAU C，et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases：Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology（ESC）［J］. Eur Heart J，2014，35（41）：2873-2926.
［5] LOPES L R，SYRRIS P，GUTTMANN O P，et al. Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy［J］. Heart，2015，101（4）：294-301.
［6] MARON B J，MARON M S，SEMSARIAN C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy：a potential link to sudden death in the absence of conventional risk factors［J］. Heart Rhythm，2012，9（1）：57-63.
［7] ARAGAM K G，NATARAJAN P. Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk：Clinical Perspectives and Basic Implications［J］. Circ Res，2020，126（9）：1159-1177.
［8] WEEKE P，RODEN D M. Pharmacogenomics and cardiovascular disease［J］. Curr Cardiol Rep，2013，15（7）：376.
［9] PATRINOS G P. Population pharmacogenomics：impact on public health and drug development［J］. Pharmacogenomics，2018，19（1）：3-6.
［10] DOLL S，DREßEN M，GEYER P E，et al. Region and cell-type resolved quantitative proteomic map of the human heart［J］.Nat Commun，2017，8（1）：1469.
［11] HERRINGTON D M，MAO C，PARKER S J，et al. Proteomic Architecture of Human Coronary and Aortic Atherosclerosis［J］.Circulation，2018，137（25）：2741-2756.
［12] GANZ P，HEIDECKER B，HVEEM K，et al. Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease［J］. JAMA，2016，315（23）：2532-2541.
［13] DAI D F，HSIEH E J，CHEN T，et al. Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides［J］. Circ Heart Fail，2013，6（5）：1067-1076.
［14] STENEMO M，NOWAK C，BYBERG L，et al. Circulating proteins as predictors of incident heart failure in the elderly［J］.Eur J Heart Fail，2018，20（1）：55-62.
［15] SABATINE M S，LIU E，MORROW D A，et al. Metabolomic identification of novel biomarkers of myocardial ischemia［J］.Circulation，2005，112（25）：3868-3875.
［16] WISNESKI J A，GERTZ E W，NEESE R A，et al. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans［J］. J Clin Invest，1987，79（2）：359-366.
［17] CHENG M L，WANG C H，SHIAO M S，et al. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure：diagnostic and prognostic value of metabolomics［J］. J Am Coll Cardiol，2015，65（15）：1509-1520.
［18] ARNTZ R M，VAN DEN BROEK S M，VAN UDEN I W，et al. Accelerated development of cerebral small vessel disease in young stroke patients［J］. Neurology，2016，87（12）：1212-1219.
［19] HOBBS F D R，BANKHEAD C，MUKHTAR T，et al. Clinical workload in UK primary care：a retrospective analysis of 100 million consultations in England，2007-14［J］. Lancet，2016，387（10035）：2323-2330.